Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company founded in 2009 that specializes in developing an advanced immune medicine platform. The firm utilizes a proprietary immunosequencing platform that integrates chemistry, computational biology, and machine learning to decode the adaptive immune system. Their primary clinical diagnostic product, clonoSEQ, is designed to detect and monitor Minimal Residual Disease in cancer patients, providing critical data for treatment efficacy. By leveraging these technical capabilities, the company supports life sciences research, clinical diagnostics, and drug discovery applications.

Operating with 500-1,000 employees across five locations, Adaptive Biotechnologies maintains a robust organizational structure focused on innovation and clinical excellence. Meet Adaptive Biotechnologies's team to understand the leadership driving their research and development initiatives. The company has established strategic collaborations with industry leaders like Genentech and Microsoft to advance neoantigen-directed T cell therapies and early disease detection diagnostics. These partnerships underscore their commitment to integrating high-throughput data with clinical practice to improve patient outcomes.

Publicly traded under the ticker NASDAQ: ADPT, the company demonstrates significant market presence within the business services and biotechnology sectors. With annual revenue reaching $308.1M, Adaptive Biotechnologies continues to scale its operations through strategic funding rounds and commercial expansion. Explore financial highlights to review detailed metrics regarding their fiscal performance and investment history. As a pioneer in immunomics, the firm remains focused on translating complex biological data into actionable clinical insights, positioning itself as a key player in the evolving landscape of precision medicine and therapeutic discovery.